Spyre Therapeutics Inc. Common Stock (SYRE)
Stock · NASDAQ · Health Care
$79.95as of 10/16/2026
Price chart
Active signals
Support level
$70.46
Industry
Biotechnology: Pharmaceutical Preparations
SYRE Signal Track Record
How signals performed across all stocks →What SYRE's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | +1.1% | 53% | October 6, 2026 |
| Bollinger Band Breakdown | 21 | -4.2% | 48% | October 6, 2026 |
| Bollinger Band Breakout | 22 | +14.9% | 59% | August 18, 2026 |
| 200-Day Moving Average TouchActive now | 9 | +17.0% | 67% | November 14, 2024 |
| Any 20-session window (baseline) | +1.0% | 52% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About SYRE
Spyre Therapeutics, Inc., a clinical stage biotechnology company, focuses on developing therapeutics for patients living with inflammatory bowel disease (IBD) and rheumatic diseases. The company develops SPY001, a humanized monoclonal immunoglobulin G1 antibody that is in phase-2 clinical stage designed to bind selectively to the a4ß7 integrin being developed for the treatment of IBD (ulcerative colitis and Crohn's d…
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Employees
- 125
- Website
- spyre.com/
Fundamentals
- 1-day range
- $78.13$80.52
- Market cap
- $9.12B
- P/E (trailing)
- —
- P/E (forward)
- -22.68
- EPS (trailing)
- $-2.32
- Dividend yield
- —
- Beta
- 3.19
- Avg. volume
- 1.20M
52-week range
$21.01$110.18
Next earnings: November 3, 2026 · EPS estimate $-0.82confirmed
Forecasts
15 analyst ratings
Buy 91%
Hold 9%
Sell 0%
1-year price forecast
High
$130
+62.6%
Median
$121
+51.3%
Low
$97
+21.3%
Spyre Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- SYRESpyre Therapeutics Inc. Common Stock$79.9▼ 0.25%Market cap $9.12BP/E —$21.01$110.18
- IONSIonis Pharmaceuticals Inc. Common Stock$42.94▼ 2.67%Market cap $9.06BP/E —$42.08$86.74
- PTGXProtagonist Therapeutics Inc. Common Stock$128.75▼ 5.71%Market cap $9.40BP/E 107.21$73.08$160.81
- RDYDr. Reddy's Laboratories Ltd Common Stock$13.07▲ 1.32%Market cap $10.11BP/E 31.61$1,101$1,415
- ALKSAlkermes plc Ordinary Shares$41.22▲ 2.79%Market cap $8.11BP/E 99.15$27$55.67
- CYTKCytokinetics Incorporated Common Stock$61.95▼ 3.08%Market cap $10.13BP/E —$54.3$88.31
- LQDALiquidia Corporation Common Stock$34.35▼ 1.24%Market cap $7.95BP/E 22.46$21.94$93.61
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| SYRE Spyre Therapeutics Inc. Common Stock | $9.12B | — | $79.9 | ▼ 0.25% | $21.01$110.18 |
| IONS Ionis Pharmaceuticals Inc. Common Stock | $9.06B | — | $42.94 | ▼ 2.67% | $42.08$86.74 |
| PTGX Protagonist Therapeutics Inc. Common Stock | $9.40B | 107.21 | $128.75 | ▼ 5.71% | $73.08$160.81 |
| RDY Dr. Reddy's Laboratories Ltd Common Stock | $10.11B | 31.61 | $13.07 | ▲ 1.32% | $1,101$1,415 |
| ALKS Alkermes plc Ordinary Shares | $8.11B | 99.15 | $41.22 | ▲ 2.79% | $27$55.67 |
| CYTK Cytokinetics Incorporated Common Stock | $10.13B | — | $61.95 | ▼ 3.08% | $54.3$88.31 |
| LQDA Liquidia Corporation Common Stock | $7.95B | 22.46 | $34.35 | ▼ 1.24% | $21.94$93.61 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- UBS Initiates Coverage On Spyre Therapeutics with Buy Rating, Announces Price Target of $120benzinga · 10/12/2026
- Spyre Therapeutics (SYRE) Completed A $350 Million Public Stock OfferingYahoo · 10/8/2026
- Spyre: Maintain 'Strong Buy' On Additional SPY072 Shots On Goal Q4 2026 And IBD Combination PotentialSeekingAlpha · 10/7/2026
- Spyre Therapeutics Sinks 14% on Upsized $350 Million Stock Offering Priced Below MarketYahoo · 10/6/2026
- Crude Oil Edges Lower; Lamb Weston Shares Surge Following Upbeat Q1 EarningsBenzinga · 10/6/2026
- Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common StockYahoo · 10/6/2026
- Spyre Therapeutics stock falls on public offering launchYahoo · 10/5/2026
- Spyre Therapeutics Announces Proposed Public Offering of its Common StockYahoo · 10/5/2026
- Spyre Therapeutics Announces Grants of Inducement AwardsYahoo · 10/2/2026
Insider Activity
Insider Actions →Acquired
36.4K
Disposed
47.2K
- King-Jones Heidy · October 1, 2026 · Option Exercise28.9K @ $14.5
- King-Jones Heidy · October 1, 2026 · Sale2.6K @ $93.46
- King-Jones Heidy · October 1, 2026 · Sale2.1K @ $92.7
- King-Jones Heidy · October 1, 2026 · Sale7.2K @ $91.35
- King-Jones Heidy · October 1, 2026 · Sale16.6K @ $90.35
- King-Jones Heidy · October 1, 2026 · Sale400 @ $89.24
- Cameron Turtle · October 1, 2026 · Sale100 @ $93.91
- Cameron Turtle · October 1, 2026 · Sale5.0K @ $93.37
- Cameron Turtle · October 1, 2026 · Sale4.0K @ $92.31
- Cameron Turtle · October 1, 2026 · Sale2.6K @ $91.49
- Cameron Turtle · October 1, 2026 · Sale2.7K @ $90.1
- Cameron Turtle · October 1, 2026 · Sale600 @ $89.14
- Scott L. Burrows · October 1, 2026 · Option Exercise7.5K @ $14.5
- Scott L. Burrows · October 1, 2026 · Sale229 @ $93.57
- Scott L. Burrows · October 1, 2026 · Sale3.1K @ $92.95
Institutional Ownership
March 31, 2026
- Total shares held
- 80.81M
- Total value held
- $3.99B
- Institutional holders
- 192
Top holders this quarter
- Unknown11.78M
- Unknown5.52M
- Unknown4.17M
- Unknown4.02M
- Unknown3.78M
- Unknown3.69M
- Unknown3.06M
- Unknown2.79M
- Unknown2.61M
- Unknown1.96M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 6, 2026
Spyre Therapeutics Launches $350M Public Offering, Stock Drops
Spyre Therapeutics has priced a $350 million public offering of common stock, which led to a decline in the share price on the launch day. The company also announced inducement awards to support its growth. Analysts from JP Morgan and BTIG have begun coverage, citing a target price around $110 to $121. The offering and analyst interest may influence the stock’s short‑term trajectory.
Spyre Therapeutics Launches $350M Public Offering, Stock Drops. Spyre Therapeutics has priced a $350 million public offering of common stock, which led to a decline in the share price on the launch day. The company also announced inducement awards to support its growth. Analysts from JP Morgan and BTIG have begun coverage, citing a target price around $110 to $121. The offering and analyst interest may influence the stock’s short‑term trajectory.